Here's an excerpt from the companies website so you know I am not just pulling it out of my butt.
"After Glaxo returned the RheothRx program, CytRx investigated the source of the renal dysfunction and determined the elevation in serum creatinine was attributable to preferential absorption of certain low molecular weight substances by the proximal tubule epithelial cells in the kidney. CytRx developed a proprietary method of manufacture based on supercritical fluid chromatography that reduced the level of these low molecular weight substances present in poloxamer 188, creating what is now known as purified poloxamer 188. Nonclinical testing of purified poloxamer 188 (now known as MST-188), demonstrated less accumulation in kidney tissue, less pronounced vacuolization of proximal tubular epithelium, more rapid recovery from vacuolar lesions, and less effect on serum creatinine. A full report of the differential effects of commercial-grade and purified poloxamer 188 on renal function has been published."
Ok. I stand corrected. It seems like the company is looking at IV administration of Triferic. If that's the case, then it has to be given frequently due to the mechanism of how Triferic works.
"Triferic delivers iron slowly and continuously in a physiologic manner during every hemodialysis session. Triferic is infused directly into the bloodstream in a small, continuous dose three times per week and is designed to replace the 5-7 mg of dialytic iron that is lost during every dialysis treatment. This mode of delivery maintains patient hemoglobin within a target range and reducing ESA utilization. With current IV iron therapy, iron levels are not always adequate when ESA’s are dosed and therefore greater ESA doses are needed; this is believed to contribute to Hgb variability and related adverse consequences."
I agree. PE ratio is not useful here and any other developmental biotechs. Use Discounted Cash Flow(DCF) instead. Also, forget the idea that Triferic will be used for other indications other than preventing iron loss during dialysis treatment.
It's acting like it's top heavy now. Need to clear to 7.50 resistance with conviction (high volume).
If the management have been forthright about the dilution then it would have been ok. The problem is, they were painting the picture that everything is fine and no need for dilution and then BOOM! Btw, do you mind lending me a sitz bath? It really hurts for me to sit lately and I can't afford to buy one now.
You're obviously not keeping up with my posts. I already covered at 6.40 yesterday and went long again.
But you also have to take into account the incidence rate of the disease. Cystic Fibrosis is far more common than Fabry's. I have been in practice for a while and have yet to see a patient with that condition.
CEO is touting that Fabry's market opportunity is 1 B. If they capture 50% of market, that's about where we are right now. Other drugs in the pipeline are still at therr infancy so no added value there.